Loading patent…
AssigneesOmeros Corporation, Leicester, University of
InventorsHans-Wilhelm Schwaeble, Cordula Margaret Stover, Clark E. Tedford, James B. Parent, Teizo Fujita
Estimating the term…
In one aspect, the invention provides methods of inhibiting the effects of MASP-2-dependent complement activation in a living subject. The methods comprise the step of administering, to a subject in need thereof, an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent inhibits cellular injury associated with MASP-2-mediated alternative complement pathway activation, while leaving the classical (C1q-dependent) pathway component of the immune system intact. In another aspect, the invention provides compositions for inhibiting the effects of lectin-dependent complement activation, comprising a therapeutically effective amount of a MASP-2 inhibitory agent and a pharmaceutically acceptable carrier.
A method of inhibiting MASP-2-dependent complement activation in a subject suffering from or at risk of a condition associated with an ischemia-reperfusion injury, comprising administering to the subject an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
16-27. (canceled)
A method of treating a subject suffering from or at risk of a MASP-2-dependent complement mediated condition associated with an ischemia-reperfusion injury comprising administering an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation.
30-58. (canceled)
Dependencies are inferred from the claim text.